Swiss pharmaceutical company Novartis is investing $300 million ($288 million) in biotherapeutics development, which includes a new $100 million biologics hub at its home base in Basel.
This content was published on
1 minute
swissinfo.ch/mga
Português
pt
Novartis vai gastar 300 milhões de dólares em bioterapias
A further $110 million will be spent on research and production at a Novartis site in Slovenia and $60 million in Austria, the company announcedExternal link on Monday.
Biotherapeutics is a growing class of medicaments which are extracted or synthesized from biological material, including proteins, cells and genes to treat such conditions as cancer and autoimmune diseases.
“Across the industry, biotherapeutics account for almost one-half of all recent new drug approvals and have enormous potential to address unmet need across a wide range of diseases,” said Reto Fischer, Head of Technical Research Division, Global Drug Development.
The new Swiss biologics hub will be created on the Basel St Johann campus in Basel to complement the company’s existing NIBR biologics centre.
The Basel-headquartered Novartis, one of the world’s largest pharmaceutical companies, is currently undergoing a restructuring process. In June, it announced that 8,000 jobs would be cut from its 108,000 global work force. The 1,400 Swiss jobs that will disappear represents some 10% of the staff it employs in its home market.
Should Switzerland take measures to support its struggling industries?
Industrial policies are back in fashion, not only in the United States but also in the EU. Should Switzerland, where various industries are struggling, draw inspiration from such policies?
Milei orders Argentina’s withdrawal from the World Health Organization
This content was published on
Argentina’s president, Javier Milei, has announced plans to pull the country out of the Geneva-headquartered World Health Organization (WHO).
‘Europe’ initiative halts signature collection to focus on Swiss-EU treaty
This content was published on
The initiative sought to embed Swiss-EU relations in the Federal Constitution, but the organisers have now stopped signature collection.
Swiss study sheds light on link between obesity and metabolic diseases
This content was published on
ETH Zurich researchers collected cells from overweight individuals to identify biological markers that raise the risk of metabolic diseases.
Swiss retail sector sees slight decline despite strong online sales
This content was published on
Black Friday, which performed well in some areas of Switzerland, and Christmas sales could not make up for the losses of previous months.
Over 6,000 Swiss companies go bankrupt but start-ups see growth
This content was published on
Switzerland recorded a spike in bankruptcies last year, but there was also a rise in new start-ups. Trends varied significantly by region and sector.
Basel greenlights funding for Eurovision Village 2025
This content was published on
MCH Group Ltd. is set to receive CHF1 million ($1.1 million) for the Eurovision Village at the Eurovision Song Contest 2025 in Basel.
Geneva researchers discover potential for targeted cancer drug delivery
This content was published on
Researchers in Geneva have discovered how some bacteria inject dangerous enzymes into cells, potentially enabling targeted drug delivery to cancer cells.
Macron denies involvement in Nestlé Waters scandal
This content was published on
French President Emmanuel Macron denied any “agreement” or “collusion” with the Swiss company Nestlé over the bottled water scandal on Tuesday.
This content was published on
The recent decision by the Swiss drugmaker to shed 7% of its workforce is more than just a cost-cutting measure - it’s a turning point for Novartis.
Novartis job cuts to heavily impact management roles
This content was published on
Of the 1,400 job cuts announced by the pharma giant in Switzerland, up to half of them will involve executive-level staff.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.